Alliancebernstein L.P. Purchases 755,035 Shares of Glaukos Co. (NYSE:GKOS)

Alliancebernstein L.P. raised its stake in Glaukos Co. (NYSE:GKOS - Free Report) by 1,235.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 816,153 shares of the medical instruments supplier's stock after purchasing an additional 755,035 shares during the period. Alliancebernstein L.P. owned 1.48% of Glaukos worth $122,374,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. IFP Advisors Inc acquired a new stake in Glaukos in the 4th quarter valued at $43,000. Asset Planning Inc acquired a new position in shares of Glaukos during the fourth quarter valued at about $90,000. Picton Mahoney Asset Management bought a new stake in shares of Glaukos during the fourth quarter worth about $125,000. SBI Securities Co. Ltd. acquired a new stake in shares of Glaukos in the 4th quarter worth about $153,000. Finally, Smartleaf Asset Management LLC lifted its position in Glaukos by 275.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,100 shares of the medical instruments supplier's stock valued at $164,000 after acquiring an additional 807 shares in the last quarter. Institutional investors and hedge funds own 99.04% of the company's stock.

Glaukos Stock Performance

GKOS traded up $2.22 on Monday, hitting $85.87. The company's stock had a trading volume of 1,996,174 shares, compared to its average volume of 622,234. The company's 50 day simple moving average is $122.46 and its 200-day simple moving average is $134.38. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. Glaukos Co. has a 12 month low of $77.91 and a 12 month high of $163.71. The firm has a market cap of $4.86 billion, a P/E ratio of -29.92 and a beta of 0.88.

Remove Ads

Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.02). Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. The company had revenue of $105.50 million for the quarter, compared to analysts' expectations of $100.72 million. Analysts forecast that Glaukos Co. will post -1.08 EPS for the current year.

Insider Activity

In other news, CFO Alex R. Thurman sold 1,520 shares of the business's stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $106.84, for a total transaction of $162,396.80. Following the completion of the transaction, the chief financial officer now owns 53,431 shares of the company's stock, valued at approximately $5,708,568.04. The trade was a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Tomas Navratil sold 3,416 shares of the firm's stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $147.14, for a total transaction of $502,630.24. Following the completion of the sale, the insider now directly owns 72,437 shares in the company, valued at $10,658,380.18. This represents a 4.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.40% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several analysts have recently commented on GKOS shares. Needham & Company LLC increased their price objective on Glaukos from $149.00 to $176.00 and gave the stock a "buy" rating in a research note on Friday, February 21st. Mizuho raised Glaukos from a "neutral" rating to an "outperform" rating and increased their price target for the company from $140.00 to $200.00 in a research report on Wednesday, February 19th. Wells Fargo & Company raised their price objective on Glaukos from $153.00 to $160.00 and gave the company an "overweight" rating in a research note on Friday, February 21st. Citigroup upgraded shares of Glaukos from a "neutral" rating to a "buy" rating and upped their target price for the stock from $132.00 to $162.00 in a research note on Wednesday, December 11th. Finally, Truist Financial raised their price target on shares of Glaukos from $152.00 to $185.00 and gave the company a "buy" rating in a research report on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $163.25.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.